BLX 0200
Alternative Names: BLX-0200Latest Information Update: 15 Mar 2023
At a glance
- Originator Biolexis Therapeutics
- Class Small molecules
- Mechanism of Action HDAC6 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 31 Aug 2022 Biolexis Therapeutics plans a phase I trial in Q1 2025 (Biolexis Therapeutics pipeline, August 2022)
- 30 Aug 2022 Biolexis Therapeutics intends to submit IND application in Q1 2024 (Biolexis Therapeutics pipeline, August 2022)
- 30 Aug 2022 BLX 0200 is available for licensing as of 30 Aug 2022. https://biolexistx.com/